ATE341545T1 - Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase - Google Patents

Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase

Info

Publication number
ATE341545T1
ATE341545T1 AT02745602T AT02745602T ATE341545T1 AT E341545 T1 ATE341545 T1 AT E341545T1 AT 02745602 T AT02745602 T AT 02745602T AT 02745602 T AT02745602 T AT 02745602T AT E341545 T1 ATE341545 T1 AT E341545T1
Authority
AT
Austria
Prior art keywords
quinoline derivatives
tyrosine kinase
kinase inhibitors
containment
medicament
Prior art date
Application number
AT02745602T
Other languages
English (en)
Inventor
Laurent Francois And Hennequin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE341545T1 publication Critical patent/ATE341545T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
AT02745602T 2001-07-16 2002-07-10 Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase ATE341545T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01401895 2001-07-16
EP01403123 2001-12-05

Publications (1)

Publication Number Publication Date
ATE341545T1 true ATE341545T1 (de) 2006-10-15

Family

ID=26077248

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02745602T ATE341545T1 (de) 2001-07-16 2002-07-10 Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase

Country Status (8)

Country Link
US (1) US7501516B2 (de)
EP (1) EP1409481B1 (de)
JP (1) JP4326328B2 (de)
AT (1) ATE341545T1 (de)
DE (1) DE60215178T2 (de)
ES (1) ES2272737T3 (de)
HK (1) HK1063185A1 (de)
WO (1) WO2003008409A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ523702A (en) 2000-08-21 2004-08-27 Astrazeneca Ab Quinazoline derivatives
EP1326859A1 (de) 2000-10-13 2003-07-16 AstraZeneca AB Chinazoline derivate mit aktivität gegen tumore
AU2001292137A1 (en) 2000-10-13 2002-04-22 Astrazeneca Ab Quinazoline derivatives
JP2004514718A (ja) 2000-11-02 2004-05-20 アストラゼネカ　アクチボラグ 抗癌剤としての置換キノリン類
ATE409185T1 (de) 2001-04-19 2008-10-15 Astrazeneca Ab Chinazolin derivate
AU2002347359A1 (en) * 2001-12-05 2003-06-17 Astrazeneca Ab Quinoline derivatives
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
AU2003281193A1 (en) 2002-07-09 2004-01-23 Astrazeneca Ab Quinazoline derivatives for use in the treatment of cancer
GB0225579D0 (en) 2002-11-02 2002-12-11 Astrazeneca Ab Chemical compounds
RU2350618C2 (ru) 2002-11-04 2009-03-27 Астразенека Аб ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
WO2004069249A1 (en) * 2003-02-03 2004-08-19 Astrazeneca Ab 3-cyano-quinoline derivatives as non-receptor tyrosine kinase inhibitors
WO2004069250A1 (en) * 2003-02-03 2004-08-19 Astrazeneca Ab 3-cyano-quinoline derivatives as non-receptor tyrosine kinase inhibitors
GB0318422D0 (en) * 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
AU2004298448B2 (en) 2003-12-18 2010-09-09 Janssen Pharmaceutica N.V. Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents
US7842701B2 (en) 2004-02-19 2010-11-30 Takeda Pharmaceutical Company Limited Pyrazoloquinolone derivative and use thereof
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
EP2044084B1 (de) * 2006-07-13 2016-02-17 Janssen Pharmaceutica NV Mtki-derivate des chinazolins
US20110281909A1 (en) 2007-08-15 2011-11-17 Glaxo Group Limited Substituted quinoline derivatives as h1 receptor antagonists
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
WO2011153942A1 (zh) * 2010-06-09 2011-12-15 天津和美生物技术有限公司 氰基喹啉衍生物
CN108064274A (zh) 2014-07-30 2018-05-22 耶达研究及发展有限公司 用于培养多能干细胞的培养基
BR112018006873A2 (pt) 2015-10-05 2018-11-06 The Trustees Of Columbia University In The City Of New York ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias
US11427559B2 (en) 2018-02-20 2022-08-30 Teligene Ltd. Substituted quinolines useful as kinase inhibitors
EP3914698A1 (de) 2019-01-23 2021-12-01 Yeda Research and Development Co. Ltd Kulturmedien für pluripotente stammzellen

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT100905A (pt) 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
AU2096895A (en) * 1994-03-07 1995-09-25 Sugen, Incorporated Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
WO1997044322A1 (en) 1996-05-20 1997-11-27 Darwin Discovery Limited Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors
SK283162B6 (sk) 1996-05-20 2003-03-04 Darwin Discovery Limited Karboxamid chinolínu ako inhibítor faktora nekrotizujúceho nádor, inhibítor fosfodiesterázy-IV a farmaceutický prostriedok s jeho obsahom
AU733551B2 (en) 1996-09-25 2001-05-17 Astrazeneca Ab Qinoline derivatives inhibiting the effect of growth factors such as VEGF
EP0946541B1 (de) 1996-11-06 2003-07-30 Darwin Discovery Limited Chinoline und deren therapeutische verwendung
GB9712761D0 (en) 1997-06-17 1997-08-20 Chiroscience Ltd Quinolines and their therapeutic use
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6288082B1 (en) * 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
DK1117659T3 (da) 1998-09-29 2004-03-22 Wyeth Corp Substituerede 3-cyanoquinoliner som hæmmere af proteintyrosinkinaser
EP1154774B1 (de) * 1999-02-10 2005-06-22 AstraZeneca AB Chinazolinderivate als angiogenesehemmer
GB9904103D0 (en) 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
GB9910577D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
BR0013219A (pt) 1999-08-12 2002-04-23 American Cyanamid Co Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto
EP1294709A2 (de) 2000-01-28 2003-03-26 AstraZeneca AB Chinolinderivate und deren verwendung als aurora 2 kinase inhibitoren
AR035851A1 (es) 2000-03-28 2004-07-21 Wyeth Corp 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
NZ523702A (en) 2000-08-21 2004-08-27 Astrazeneca Ab Quinazoline derivatives
EP1326859A1 (de) 2000-10-13 2003-07-16 AstraZeneca AB Chinazoline derivate mit aktivität gegen tumore
AU2001292137A1 (en) 2000-10-13 2002-04-22 Astrazeneca Ab Quinazoline derivatives
JP2004512335A (ja) 2000-10-25 2004-04-22 アストラゼネカ　アクチボラグ キナゾリン誘導体
EP1337513A1 (de) 2000-11-02 2003-08-27 AstraZeneca AB 4-substituierte chinoline als antitumormittel
JP2004514718A (ja) 2000-11-02 2004-05-20 アストラゼネカ　アクチボラグ 抗癌剤としての置換キノリン類
ATE409185T1 (de) 2001-04-19 2008-10-15 Astrazeneca Ab Chinazolin derivate
EP1408971A4 (de) 2001-06-21 2006-01-25 Ariad Pharma Inc Neue chinoline und ihre verwendungszwecke
AU2002347359A1 (en) 2001-12-05 2003-06-17 Astrazeneca Ab Quinoline derivatives
GB0129099D0 (en) 2001-12-05 2002-01-23 Astrazeneca Ab Chemical compounds
WO2003048159A1 (en) 2001-12-05 2003-06-12 Astrazeneca Ab Quinoline derivatives
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives

Also Published As

Publication number Publication date
EP1409481B1 (de) 2006-10-04
JP2004536860A (ja) 2004-12-09
DE60215178T2 (de) 2007-08-23
US7501516B2 (en) 2009-03-10
US20050009867A1 (en) 2005-01-13
EP1409481A1 (de) 2004-04-21
HK1063185A1 (en) 2004-12-17
WO2003008409A1 (en) 2003-01-30
JP4326328B2 (ja) 2009-09-02
ES2272737T3 (es) 2007-05-01
DE60215178D1 (de) 2006-11-16

Similar Documents

Publication Publication Date Title
ATE341545T1 (de) Quinolin-derivate und ihre verwendung als inhibitoren der tyrosine kinase
NO20025792D0 (no) Kinazolinderivater for behandling av tumorer
ATE353888T1 (de) Chinazolinderivate
MY129809A (en) Quinazoline derivatives
DE602004011199D1 (de) 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren
NO20061415L (no) Kinazolinderivater
ATE409185T1 (de) Chinazolin derivate
ATE400570T1 (de) 2,4,6-trisubstituierte pyrimidine als inhibitoren von phosphatidylinosit-(pi-)3-kinase und deren verwendung bei der behandlung von krebs
UA88012C2 (uk) Похідні хіназоліндіону як інгібітори parp
SG154433A1 (en) Phthalazine derivatives as parp inhibitors
SE0301700D0 (sv) Novel compounds
ES2195785A1 (es) Nuevos derivados de piridazin-3(2h)-ona.
ATE296826T1 (de) Pyrazolo(1,5)pyridinderivate
IS2855B (is) 4-anilínókínasólínafleiður sem andfjölgunarefni
SG154434A1 (en) Quinazolinone derivatives as parp inhibitors
GB0124933D0 (en) Chemical compounds
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
ATE300541T1 (de) Pyrazolopyridinderivate
NO20051900L (no) Kinazolinderivater som SRC tyrosin kinase inhibitorer
MXPA04002042A (es) Compuestos de bencimidazol sustituidos y su uso para el tratamiento del cancer.
ATE287886T1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer
WO2003053960A3 (en) Quinline derivates and their use as mek inhibitors
ATE429230T1 (de) Chinazoline derivative und ihre anwendung in der krebsbehandlung
ATE274515T1 (de) Pyrazolopyridinderivate
ATE373000T1 (de) Pyrazolopyridin-derivate als antiherpesmittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties